Viking Therapeutics, Inc. Stock Deutsche Boerse AG
Stocks
1VT
US92686J1060
Biotechnology & Medical Research
|
Real-time Estimate
Tradegate
20:32:00 15/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 23.82 EUR | +0.74% |
|
-9.60% | -28.38% |
| Market Cap | 2.97B 2.65B 2.46B 2.24B 4.22B 281B 4.29B 29.61B 11.58B 147B 11.15B 10.91B 470B | P/E 2026 * |
-5.54x | P/E 2027 * | -5.95x |
|---|---|---|---|---|---|
| Enterprise Value | 2.51B 2.24B 2.08B 1.89B 3.56B 238B 3.62B 24.99B 9.78B 124B 9.41B 9.21B 397B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
97.16% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| VKTX | Delayed | |
CBOE
| VKTX | Real-time | |
|
Tradegate
| 1VT | Real-time | |
|
Boerse Muenchen
| 1VT | Real-time | |
|
Xetra
| 1VT | Delayed | |
|
London S.E.
| 0VQA | Delayed | |
|
Borsa Italiana
| 1VKTX | End-of-day quote | |
|
Deutsche Boerse AG
| 1VT | Delayed | |
|
Börse Stuttgart
| 1VT | Delayed |
Last Transcript: Viking Therapeutics, Inc.
| 1 day | +0.74% | ||
| 1 week | -9.60% | ||
| Current month | -20.56% | ||
| 1 month | -12.23% | ||
| 3 months | -30.99% | ||
| 6 months | -25.78% | ||
| Current year | -28.38% |
| 1 week | 22.55 |  | 26 |
| 1 month | 22.55 | | 38 |
| Current year | 21.84 | | 38 |
| 1 year | 21.84 | | 38 |
| 3 years | 8.62 | | 91.5 |
| 5 years | 1.92 | | 91.5 |
| 10 years | 0.77 | | 91.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
Brian Lian
CEO | Chief Executive Officer | 60 | 24/09/2012 |
Gregory Zante
DFI | Director of Finance/CFO | 55 | 04/01/2021 |
Hubert Chen
CTO | Chief Tech/Sci/R&D Officer | 57 | 11/06/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
Lawson Macartney
CHM | Chairman | 68 | 01/05/2015 |
Brian Lian
CHM | Chairman | 60 | 24/09/2012 |
Matthew Foehr
BRD | Director/Board Member | 53 | 01/05/2014 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.74% | -9.60% | - | - | 2.97B | |
| +0.21% | -7.67% | +61.07% | +71.32% | 68.92B | |
| +1.66% | +7.51% | +8.12% | +61.40% | 51.9B | |
| +3.14% | +7.17% | +12.48% | +41.70% | 48.73B | |
| +2.75% | +3.82% | +32.33% | +35.08% | 43.13B | |
| -1.33% | +1.92% | +286.86% | +461.93% | 41.48B | |
| +5.51% | +5.72% | +17.09% | +112.81% | 39.96B | |
| +1.28% | -0.76% | +12.67% | +45.10% | 30.6B | |
| -2.21% | -14.22% | +40.33% | -0.94% | 26.01B | |
| +1.70% | -2.10% | -13.62% | -7.05% | 22.27B | |
| Average | +1.33% | -3.90% | +50.82% | +91.26% | 41.44B | |
| Weighted average by Cap. | +1.46% | -3.49% | +54.55% | +97.89% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -542M -483M -449M -409M -769M -51.29B -783M -5.4B -2.11B -26.76B -2.03B -1.99B -85.64B | -535M -478M -444M -404M -760M -50.69B -773M -5.33B -2.09B -26.45B -2.01B -1.97B -84.62B |
| Net Debt | -463M -414M -384M -350M -658M -43.89B -670M -4.62B -1.81B -22.9B -1.74B -1.7B -73.28B | -511M -456M -424M -385M -725M -48.38B -738M -5.09B -1.99B -25.24B -1.92B -1.88B -80.78B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/10/26 | €22.60 | -4.44% | 88 |
| 14/10/26 | €23.65 | -1.46% | 0 |
| 13/10/26 | €24.00 | -7.69% | 150 |
| 12/10/26 | €26.00 | +1.17% | 24 |
| 09/10/26 | €25.70 | +2.80% | 588 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- VKTX Stock
- 1VT Stock
Select your edition
All financial news and data tailored to specific country editions
